Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
Authors
Keywords
-
Journal
Frontiers in Neuroscience
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-09-07
DOI
10.3389/fnins.2018.00609
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Microglia and Aging: The Role of the TREM2–DAP12 and CX3CL1-CX3CR1 Axes
- (2018) Carmen Mecca et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Past and the Future of Alzheimer’s Disease Fluid Biomarkers
- (2018) Kaj Blennow et al. JOURNAL OF ALZHEIMERS DISEASE
- Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease
- (2018) Frederic Brosseron et al. Alzheimers Research & Therapy
- Complex role of chemokine mediators in animal models of Alzheimer's Disease
- (2018) Elodie Martin et al. Biomedical Journal
- Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
- (2018) Daniel Alcolea et al. JOURNAL OF ALZHEIMERS DISEASE
- microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer’s Disease
- (2017) Patricia R. Manzine et al. JOURNAL OF ALZHEIMERS DISEASE
- Absence of CX3CR1 impairs the internalization of Tau by microglia
- (2017) Marta Bolós et al. Molecular Neurodegeneration
- CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration
- (2017) Daniel Alcolea et al. NEUROLOGY
- Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus
- (2017) Ling Guo et al. Experimental and Therapeutic Medicine
- Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms
- (2017) Kristina Endres et al. Frontiers in Molecular Neuroscience
- 2016 Alzheimer's disease facts and figures
- (2016) Alzheimers & Dementia
- sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
- (2016) Marc Suárez‐Calvet et al. EMBO Molecular Medicine
- Melatonin administration reverses the alteration of amyloid precursor protein-cleaving secretases expression in aged mouse hippocampus
- (2016) Sujira Mukda et al. NEUROSCIENCE LETTERS
- CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection
- (2016) Peiqing Chen et al. Biomed Research International
- Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
- (2015) Daniel Alcolea et al. NEUROLOGY
- Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage
- (2013) G. K. Sheridan et al. Open Biology
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use
- (2011) Giovanni B. Frisoni et al. INTERNATIONAL PSYCHOGERIATRICS
- ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons
- (2010) Peer-Hendrik Kuhn et al. EMBO JOURNAL
- Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity
- (2009) Minji Kim et al. HUMAN MOLECULAR GENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More